Clovis da Fonseca

NeOnc Technologies, Inc. operates as a cancer biotechnology company, develops intranasal inhalation and other nontraditional delivery of a novel for the treatment of lung cancer, malignant brain cancer (gliomas), and other aggressive brain cancers. The company was founded by by Thomas C. Chen and Eytan J Lombroso on April 13, 2015 and is headquartered in Los Angeles, CA.

NeOnc Technologies, Inc. operates as a cancer biotechnology company, develops intranasal inhalation and other nontraditional delivery of a novel for the treatment of lung cancer, malignant brain cancer (gliomas), and other aggressive brain cancers. The company was founded by by Thomas C. Chen and Eytan J Lombroso on April 13, 2015 and is headquartered in Los Angeles, CA.

NeOnc Technologies, Inc. operates as a cancer biotechnology company, develops intranasal inhalation and other nontraditional delivery of a novel for the treatment of lung cancer, malignant brain cancer (gliomas), and other aggressive brain cancers. The company was founded by by Thomas C. Chen and Eytan J Lombroso on April 13, 2015 and is headquartered in Los Angeles, CA.

NeOnc Technologies, Inc. operates as a cancer biotechnology company, develops intranasal inhalation and other nontraditional delivery of a novel for the treatment of lung cancer, malignant brain cancer (gliomas), and other aggressive brain cancers. The company was founded by by Thomas C. Chen and Eytan J Lombroso on April 13, 2015 and is headquartered in Los Angeles, CA.

NeOnc Technologies, Inc. operates as a cancer biotechnology company, develops intranasal inhalation and other nontraditional delivery of a novel for the treatment of lung cancer, malignant brain cancer (gliomas), and other aggressive brain cancers. The company was founded by by Thomas C. Chen and Eytan J Lombroso on April 13, 2015 and is headquartered in Los Angeles, CA.